Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026

Pulmatrix, Inc.

2024-Q2 EPS reported -$1.37 revenue$7,437,000

Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.
Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.
Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.
Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.